Please login to the form below

Not currently logged in
Email:
Password:

Takeda expands Latin American footprint

Opens new subsidiary in Peru

Takeda has continued its expansion in Latin America, establishing a new sales and marketing subsidiary in Peru.

Headquartered in Lima, Takeda Peru adds to the company's existing operations in Brazil, Argentina, Mexico, Venezuela, Colombia and Ecuador.

Its latest subsidiary in the region will be led by Julio Cesar Acevedo Orrego, who was formerly marketing - promotion and sales manager for Takeda Colombia.

There he built up and headed the Takeda Sales and Marketing organisation following the company's acquisition of Farmacol Laboratories.

Takeda Peru will focus on gastroenterology, cardiology, metabolism, oncology and respiratory diseases, but with an initial focus on just four products. These will be ulcer treatments Zurcal (pantoprazole) and Riopan (Magaldrate + Dimeticone), the anti-inflammatory Faktu (Policresulen, Cinchocaine hydrochloride) and Albothyl (Policresulen), a gynaecology product.

Norbert Oppitz, senior vice president for Latin America at Takeda, said: "The launch of our subsidiary in Peru reinforces Takeda's position in Latin America and will enable us to meet the diverse healthcare needs of the population.

“We have an established product portfolio, which will give us a strong starting point and we look forward to launching our novel medicines into the market. This investment further demonstrates our commitment to Latin America and its growth potential."

Eyeing regional market growth that is expected to run at a compound annual rate of 12.5 per cent until 2017, Takeda said it plans on “building a leading position in Latin America”.

23rd August 2013

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
EPG Health

REACH, ENGAGE & MEASURE - Accomplish meaningful HCP engagement via Medthority, our trusted independent medical website. Support education and treatment...

Latest intelligence

white house
Eliminating pharmaceutical rebates, is this déjà vu?
By Andrew Parece and Matthew Majewski...
Patients are ready to embrace decentralised clinical trials, are you?
Traditional clinical trial designs simply can’t withstand the impact of COVID-19. While before the pandemic, some in clinical research were beginning to adopt virtual components, the move towards designing hybrid...
Has the pandemic opened up a future of accelerated diagnosis and better care for rare disease patients?
The challenge with rare disease is in the name – it's rare, so awareness is limited and diagnosis hindered. Could a more virtual existence change this? A Medical Affairs viewpoint...

Infographics